Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration

Pilot Study Evaluating Maraviroc (Celsentri®)Intensification Benefit in HIV Infected Patients Presenting Insufficient Immune Restoration Despite Controlled Viral Load With Antiretroviral Treatment. ANRS 145 MARIMUNO

This pilot study aims to evaluate Maraviroc intensification strategy during 24 weeks in HIV infected patients under efficient (CV< 50 cp/mL), controlled antiretroviral therapy (≥ 6 months) and uncompleted immune restoration (CD4<350 cells/mL and CD4 earning <100 cells/mL during last 24 months).

The study will include 60 patients whose follow up is carried out for 48 weeks. recruitment period will be maintained for 12 months.

Inclusion Criteria:

• HIV-1 infection
• maraviroc-naives patients
• CD4 less than 350 cells/mm3
• viral load less than 50 cp/mL and CD4 earning less than 100 cells/mm3 during last 24 months

Exclusion Criteria:

• HIV-2 infection
• X4 tropism at inclusion
• pregnancy and breast feeding
• interferon, immunomodulatory drugs treatment or anti-HIV vaccines and chemotherapy
• hypersensibility of peanut or soya